Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyThoracic TumorsDiseaseNeuroendocrine TumorsSubgroupICD10E34.0MeSHNeuroendocrine TumorsSequenceChemotherapyChemo-substanceEverolimusFluorouracilLanreotideLenvatinibOctreotideStreptozocinSunitinibChemo-substanceEverolimusFluorouracilLanreotideLenvatinibOctreotideStreptozocinSunitinibChemo-substanceEverolimusFluorouracilLanreotideLenvatinibOctreotideStreptozocinSunitinibChemo-substanceEverolimusFluorouracilLanreotideLenvatinibOctreotideStreptozocinSunitinibNo. Substances12 RadiotherapySupportive therapySupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNo. Substances4Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAbdominal PainAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaAstheniaCholelithiasisConstipationDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Exanthema, AcneiformFatigueHand-Foot SyndromeHeadacheHyperglycemiaHypertensionHypothyroidismInfectionsLeukopeniaLymphopeniaMucositisNauseaNeutropeniaOral MucositisPainProteinuriaRashThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorCapdevila JCaplin MEDilz LMMoertel CGRaymond ERinke AYao JCDiseasefortgeschrittener, gut-diff., nicht funktionaler neuroendokriner Tumor der Lunge oder gastrointestinaler Herkunft, Grad 1 und 2, WHO Status 0-1fortgeschrittener oder metastasierter pankreatisch neuroendokriner Tumorfortgeschrittener pankreatisch neuroendokriner Tumorfortgeschrittener pNET oder geNET, Zweitlinie nach TA oder SSA, ECOG 0-1NET, inoperabel oder met., Mitteldarm-Tumor oder unbek. PrimariusNET des Pankreas, met. oder nicht resezierbar, low- oder intermediate-grade, Progress innerhalb der letzten 12 MonateNET des Pankreas, met. oder nicht resezierbar, Progress innerhalb der letzten 12 Monate, ECOG 0-1neuroendokrine Tumore, gastroenteropankreatisch, unbekannter Primarius, nicht reserzierbar oder met., Ki-67 Index bis 10%, G1 u G2, ECOG 0-2OriginComprehensive Cancer Center, Mayo Clinic, Rochester, MNDept. of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charite, BerlinService Inter-Hospitalier de Cancérologie et de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, FrankreichThe CLARINET Investigators, CLARINET StudieThe Fourth Trial (RADIANT-4) Study GroupThe PROMID Study Group, PROMID StudieThe Third Trial (RADIANT-3) Study GroupVHIO, Barcelona, Spain, TALENT Trial (GETNE1509)Protocols in Revision 8 protocols foundProtocols under revision.Everolimus 10, Pancreatic Neuroendocrine Tumor (PID560)Everolimus 10, Pulmonary and Gastroenteric Neuroendocrine Tumors (PID650)Fluorouracil 400 / Streptozocin 500, Neuroendocrine Tumor (PID1399)Fluorouracil 400 / Streptozocin 500, Neuroendocrine Tumor (PID643)Lanreotide 120, Neuroendocrine Tumor (PID542)Lenvatinib 24, Gastroenteric and Pancreatic Neuroendocrine Tumors (PID2018)Octreotide LAR 30, gastroenteric and pancreatic Neuroendocrine Tumor (PID543)Sunitinib 37.5, pancreatic Neuroendocrine Tumor (PID561)